Kwangdong Healthbio

086220 · KONEX · ₩086220 · 광동헬스바이오

₩1,179▼ ₩10 (0.84%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩465

vs the current price (₩1,179)

Enterprise value
₩24B
Equity value
₩5.9B
WACC
5.5%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 61% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • To match today's price of ₩1,179, the model needs an operating margin of 2.3% every year (it uses 1.7%).
  • Or revenue growth +10.1 points a year higher than assumed in each of the 5 years.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
—
Base
₩465
−60.5%
Bull
₩4,816
+308.5%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (1.7%).

Revenue growth

  • 1.6%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (1.6% a year, annual reports), fading to 3% by year 5.

  • 1.9%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (1.6% a year, annual reports), fading to 3% by year 5.

  • 2.3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (1.6% a year, annual reports), fading to 3% by year 5.

  • 2.6%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (1.6% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (1.6% a year, annual reports), fading to 3% by year 5.

Business

  • 1.7%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 3.9%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 1.2%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 5.7%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.01%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-30.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 104 weeks of weekly returns against KOSPI (official index); raw beta 0.23, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.51%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (FY 2025)
₩67B
Net debt (borrowings and leases − cash and deposits)
₩18B
Shares
12,687,865
Share price
₩1,179
Market cap
₩15B

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩80B₩66B₩67B₩68B₩69B₩71B₩73B₩75B
Growth25.4%−18.3%2.3%1.6%1.9%2.3%2.6%3.0%
EBIT₩2.6B−₩996M₩900M₩1.2B₩1.2B₩1.2B₩1.2B₩1.3B
EBIT margin3.3%−1.5%1.3%1.7%1.7%1.7%1.7%1.7%
After-tax EBIT₩1.9B−₩722M₩653M₩839M₩855M₩874M₩897M₩924M
+ Depreciation₩2.8B₩2.7B₩2.7B₩2.7B₩2.7B₩2.8B₩2.8B₩2.9B
− Capital spending₩312M₩917M₩1.3B₩817M₩832M₩851M₩873M₩900M
− Working capital₩405M−₩1.6B−₩1.6B₩61M₩74M₩91M₩105M₩124M
Free cash flow₩4B₩2.6B₩3.6B₩2.6B₩2.7B₩2.7B₩2.8B₩2.8B
Discount factor———0.9480.8980.8510.8070.765
Present value———₩2.5B₩2.4B₩2.3B₩2.2B₩2.2B

Terminal value ₩16B, worth ₩12B today: 51% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩1,441 a share)Now 0.82×₩1,3790.96×₩2,0611.43×₩2,7351.90×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2022, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
4.5%₩606₩744₩938₩1,227₩1,707
5.0%₩437₩534₩664₩845₩1,115
5.5%₩303₩374₩465₩586₩754
6.0%₩195₩248₩314₩398₩510
6.5%₩104₩145₩194₩255₩333

Now (TTM)

Market cap
₩15B
Enterprise value
₩33B
P/E
—
P/B
0.8×
P/S
0.2×
EV/EBITDA
9.2×
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩1,574₩1,655₩2,700₩2,195₩2,495
Market cap₩20B₩21B₩34B₩28B₩32B
P/E——60.1×39.7×72.2×
P/B1.1×1.3×1.9×1.6×1.9×
P/S0.3×0.3×0.4×0.4×0.5×
EV/EBITDA10.6×26.1×10.5×12.8×17.1×
Dividend yield0.0%————

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Kwangdong Healthbio—0.8×0.2×9.2×0.0%
Samyang Foods17.6×5.6×3.1×—0.4%
Orion10.8×1.1×1.3×5.4×3.0%
CJ Cheiljedang—0.3×0.1×—3.5%
Nongshim12.3×0.8×0.7×—1.5%
Otoki17.4×0.6×0.3×—2.8%
Hite Jinro23.7×1.0×0.5×6.4×4.4%
Similar companies (median)17.4×0.9×0.6×5.9×2.9%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Kwangdong Healthbio / 광동헬스바이오 / 086220 / KRX:086220

Source: KRX statistical information